Table 1.
No risk for adverse health effects (HBM-I)[11] |
Increased risk for adverse health effects (HBM-II)[11] |
Onset of sub-clinical adverse effects on kidney function[5] |
Onset of clinical mercurialism[5] |
---|---|---|---|
No action required | Action required | ||
5 μg Hg/g Cr |
20 μg/g Cr |
50 μg Hg/g Cr |
100 μg Hg/g Cr |
or |
or |
||
7 μg Hg/L | 25 μg/L |